Additional file 1 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Osuga, Yutaka, Seki, Yoshifumi, Tanimoto, Masataka, Kusumoto, Takeru, Kudou, Kentarou, Terakawa, Naoki
2021 · doi:10.6084/m9.figshare.14821126.v1 · W6920973763
article OA: green CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-14 ⓘ

This paper presents demographic and baseline characteristics of women with endometriosis-associated pain participating in a 24-week phase 2 trial of relugolix, an oral GnRH receptor antagonist.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Additional file 1. Demographic and baseline characteristics.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-13T18:33:16.088889+00:00
License: CC0 · commercial use OK